Your browser is no longer supported. Please, upgrade your browser.
Loncar Cancer Immunotherapy ETF
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week2.02%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month4.57%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-1.82%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y6.29%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year19.36%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range26.17 - 35.82 Perf YTD-1.25%
Dividend0.28 P/FCF- EPS past 5Y- ROI- 52W High-12.56% Beta-
Dividend %0.89% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low19.68% ATR0.54
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)58.78 Volatility0.55% 1.29%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.83 Prev Close31.00
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume4.59K Price31.32
Recom- SMA201.29% SMA504.39% SMA2000.60% Volume3,824 Change1.05%
Mar-15-21 06:06PM  
Sep-18-20 05:46AM  
May-18-20 10:51AM  
Mar-26-20 12:00AM  
Jan-26-20 07:17PM  
Jan-23-20 04:15PM  
Dec-24-19 12:15PM  
Dec-23-19 12:00PM  
Dec-10-19 10:10AM  
Dec-02-19 02:40PM  
Nov-29-19 12:15PM  
Nov-21-19 12:15PM  
Nov-14-19 01:31PM  
Nov-01-19 03:18PM  
Jun-05-19 03:11PM  
Jun-03-19 02:46PM  
May-09-19 07:46AM  
Mar-20-19 07:00AM  
Mar-12-19 11:05AM  
Mar-11-19 10:59AM  
Mar-06-19 05:05PM  
Feb-06-19 02:32PM  
Aug-16-18 11:49AM  
Aug-15-18 08:00AM  
Aug-02-18 12:55PM  
Jun-28-18 06:56AM  
Apr-18-18 04:08PM  
Apr-11-18 09:26PM  
Mar-16-18 01:30PM  
Feb-28-18 02:09PM  
Feb-20-18 09:24AM  
Feb-16-18 08:00AM  
Feb-02-18 08:00AM  
Dec-20-17 08:00AM  
Dec-18-17 02:40PM  
Nov-14-17 04:18PM  
Oct-04-17 08:00AM  
Sep-01-17 02:06PM  
Aug-28-17 02:37PM  
Jun-22-17 04:02PM  
Jun-21-17 08:30AM  
Jun-02-17 06:56AM  
Nov-16-16 05:22PM  
Oct-28-16 03:31PM  
Oct-25-16 12:47PM  
Oct-14-16 08:30AM  
Aug-06-16 12:07PM  
Aug-02-16 12:09PM  
Jun-22-16 07:30AM  
Jun-01-16 09:23AM  
Apr-12-16 04:22PM  
Mar-07-16 06:37AM  
Feb-16-16 05:12AM  
Feb-10-16 09:29AM  
Feb-08-16 06:33PM  
Feb-05-16 06:46AM  
Jan-08-16 01:33PM  
Dec-16-15 07:00AM  
Dec-14-15 05:46PM  
Dec-05-15 12:01AM  
Dec-01-15 09:50AM  
Nov-30-15 11:31AM  
Oct-16-15 03:23PM  
Oct-15-15 05:15PM  
Oct-14-15 09:05AM  
The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified.